Rifampicin resistance patterns and dynamics of tuberculosis and drug-resistant tuberculosis in Enugu, South Eastern Nigeria.

INTRODUCTION Tuberculosis (TB) continues to be a public health problem globally. The burden is further exacerbated in developing countries like Nigeria, by poor diagnosis, management and treatment, as well as rapid emergence of drug-resistant TB. This study was conducted to evaluate the prevalence of drug-resistant TB, determine the rpoB gene mutation patterns of Mycobacterium tuberculosis (MTB) and model the dynamics of multidrug resistant TB (MDR-TB) in Enugu, Nigeria. METHODOLOGY A total of 868 samples, from patients accessing DOTS services in designated centres within the zone, were screened by sputum-smear microscopy, while 207 samples were screened by Nucleic Acid Amplification (Xpert® MTB/Rif) Test (NAAT). A deterministic model was formulated to study the transmission dynamics of TB and MDR-TB, using live data generated through epidemiological study. RESULTS The results showed TB prevalence values of 22.1% and 21.3% by sputum-smear and NAAT assays, respectively. Analysis of the rifampicin resistance patterns showed the highest occurrence of mutations (50%) along codons 523 - 527. Factors such as combination therapy, multiple therapy and compliance to treatment had influence on both prevalence and development of TB drug resistance in the population. CONCLUSIONS This first documentation of Rifampicin resistance patterns in MTB from Nigeria shows that a majority of rpoB gene mutations occurred along codons 523 to 527, contrary to the widely reported codon 531 mutation and that multiple interventions such as combination therapy, with good compliance to treatment are needed to reduce both prevalence and development of TB drug resistance in the population.

[1]  Shiying Li,et al.  Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis , 2019, BMC Microbiology.

[2]  Y. Pang,et al.  Additional benefits of GeneXpert MTB/RIF assay for the detection of pulmonary tuberculosis patients with prior exposure to fluoroquinolones , 2018, Infection and drug resistance.

[3]  Jing Wang,et al.  Genetic diversity of drug resistant Mycobacterium Tuberculosis in local area of Southwest China: a retrospective study , 2018, BMC Infectious Diseases.

[4]  M. Zaw,et al.  Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. , 2018, Journal of infection and public health.

[5]  A. Bowale,et al.  Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos Nigeria , 2018, African health sciences.

[6]  M. Joloba,et al.  Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda , 2018, PloS one.

[7]  B. Stray-Pedersen,et al.  Mutations in rpoB and katG genes of multidrug resistant mycobacterium tuberculosis undetectable using genotyping diagnostic methods , 2017, The Pan African medical journal.

[8]  Y. Kuyinu,et al.  Characteristics of Mycobacterium Tuberculosis Positive Patients Screened for Drug-Resistant Tuberculosis at a Tertiary Health Facility in Lagos, Nigeria. , 2017, Journal of the National Medical Association.

[9]  Egbe Kingsley,et al.  Prevalence of Tuberculosis and Rifampicin Resistance Among Patients Seeking Medical Care in Nasarawa State, North Central Nigeria , 2016 .

[10]  A. Aseffa,et al.  Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia , 2015, BMC Public Health.

[11]  M. Tesfay,et al.  Adherence to anti-tuberculosis treatment in Tigray, Northern Ethiopia. , 2014, Public Health Action.

[12]  W. Ssengooba,et al.  Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert®MTB/RIF in Kampala, Uganda: a retrospective study , 2014, BMC Infectious Diseases.

[13]  P. Nsubuga,et al.  Factors associated with interruption of treatment among Pulmonary Tuberculosis patients in Plateau State, Nigeria. 2011 , 2014, The Pan African medical journal.

[14]  A. Berhan,et al.  A Meta-Analysis of Drug Resistant Tuberculosis in Sub-Saharan Africa: How Strongly Associated with Previous Treatment and HIV Co-Infection? , 2013, Ethiopian journal of health sciences.

[15]  Suhail Ahmad,et al.  Variations in the occurrence of specific rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from patients of different ethnic groups in Kuwait , 2012, The Indian journal of medical research.

[16]  O. Oladimeji,et al.  Resistance of Mycobacterium Tuberculosis to First and Second Line AntiTuberculosis Drugs in South West, Nigeria , 2012 .

[17]  R. Jenison,et al.  Rapid Detection of rpoB Gene Mutations Conferring Rifampin Resistance in Mycobacterium tuberculosis , 2012, Journal of Clinical Microbiology.

[18]  T. Bodmer,et al.  Diagnosing pulmonary tuberculosis with the Xpert MTB/RIF test. , 2012, Journal of visualized experiments : JoVE.

[19]  C. Çavuşoğlu,et al.  Evaluation of the GeneXpert MTB/RIF Assay for Rapid Diagnosis of Tuberculosis and Detection of Rifampin Resistance in Pulmonary and Extrapulmonary Specimens , 2011, Journal of Clinical Microbiology.

[20]  M. D. Granado,et al.  WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update , 2011, European Respiratory Journal.

[21]  J. Nkengasong,et al.  Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities , 2011, Clinical Microbiology Reviews.

[22]  Carlos Castillo-Chavez,et al.  Modeling TB and HIV co-infections. , 2009, Mathematical biosciences and engineering : MBE.

[23]  Anthony S Fauci,et al.  Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research. , 2008, The Journal of infectious diseases.

[24]  L. Rigouts,et al.  Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[25]  J. Palomino.  Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field , 2005, European Respiratory Journal.

[26]  Honghai Wang,et al.  Mutations in the rpoB Gene of Multidrug-Resistant Mycobacterium tuberculosis Isolates from China , 2003, Journal of Clinical Microbiology.

[27]  I. Bastian,et al.  Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[28]  E. Salpeter,et al.  Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. , 1998, American journal of epidemiology.

[29]  P. Escalante.  Tuberculosis , 1904, Annals of Internal Medicine.

[30]  Baojun Song,et al.  Mathematical analysis of the transmission dynamics of HIV/TB coinfection in the presence of treatment. , 2008, Mathematical biosciences and engineering : MBE.